Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results, Beats Estimates By $10.18 EPS

Edgewise Therapeutics (NASDAQ:EWTX) released its quarterly earnings data on Wednesday. The company reported $9.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $10.18, reports.

Edgewise Therapeutics Trading Up 15.9%

Shares of EWTX traded up $6.17 during mid-day trading on Friday, reaching $45.04. The company’s stock had a trading volume of 3,608,214 shares, compared to its average volume of 1,283,603. Edgewise Therapeutics has a 52 week low of $16.70 and a 52 week high of $48.51. The company’s fifty day moving average price is $40.84 and its two-hundred day moving average price is $36.46. The stock has a market cap of $4.89 billion, a PE ratio of 5.50 and a beta of 0.39.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EWTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Edgewise Therapeutics in a research report on Wednesday, October 14th. Wedbush dropped their price objective on Edgewise Therapeutics from $53.00 to $51.00 and set an “outperform” rating on the stock in a research note on Thursday. Oppenheimer began coverage on shares of Edgewise Therapeutics in a research note on Thursday, July 9th. They issued an “outperform” rating and a $51.00 target price for the company. Finally, William Blair initiated coverage on Edgewise Therapeutics in a report on Friday, October 16th. They set an “outperform” rating for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $52.83.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne Donovan sold 2,919 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $43.41, for a total value of $126,713.79. Following the completion of the sale, the chief marketing officer owned 8,625 shares in the company, valued at approximately $374,411.25. This trade represents a 25.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total transaction of $784,973.28. Following the completion of the sale, the chief executive officer owned 52,488 shares of the company’s stock, valued at $2,292,675.84. This trade represents a 25.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 38,329 shares of company stock worth $1,675,529. Corporate insiders own 21.30% of the company’s stock.

Trending Headlines about Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: A report of takeover interest appears to be the main near-term catalyst behind the stock’s rise. The report does not establish that a deal has been agreed or that a transaction will occur. Edgewise Therapeutics gains amid report of takeover interest
• Positive Sentiment: The FDA gave favorable feedback on EDG-7500’s Phase 3 plan following an end-of-Phase 2 meeting. The STRATUS-HCM program is designed to study obstructive and nonobstructive HCM and is on track to begin in Q4 2026, reducing uncertainty around the development path. FDA meeting and Phase 3 update
• Neutral Sentiment: Wedbush cut its price target to $51 from $53 but kept an Outperform rating, leaving its view positive despite the modest reduction. Wedbush lowers EWTX price target
• Neutral Sentiment: Edgewise reported quarterly EPS of $9.65, well above the consensus estimate of a loss of $0.53. The unusually large reported figure may need context to assess its relevance to ongoing operations.
• Negative Sentiment: Put-option purchases were unusually high, with 2,813 contracts traded—279% above typical volume. This may reflect increased hedging or bearish positioning, though options activity alone does not confirm investor expectations.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.